Life Sciences 1993-01-01

Inhibitory effect of a peptide leukotriene antagonist ONO-1078 on LTD4- and antigen-induced thromboxane B2 production in guinea pig lungs.

T Obata, Y Okada, N Nakagawa, T Terawaki, H Aishita

Index: Life Sci. 52(12) , PL97-102, (1993)

Full Text: HTML

Abstract

The effect of a peptide leukotriene receptor antagonist ONO-1078 on the production of thromboxane (Tx) B2 induced by leukotriene (LT) D4 and antigen challenge was examined in guinea pig lungs. LTD4 (1-1,000 nM) induced a concentration-dependent production of TxB2 in non-sensitized guinea pig lungs and ovalbumin challenge (0.01-100 micrograms/ml) produced TxB2 and peptide leukotrienes in a concentration-dependent manner in ovalbumin-sensitized guinea pig lungs. ONO-1078 inhibited LTD4 (100 nM)-induced TxB2 production with the IC50 value of 0.24 microM. Furthermore, ONO-1078 inhibited antigen (10 micrograms/ml)-induced TxB2 production with the IC50 value of 0.14 microM without effect on the production of peptide leukotrienes. These results suggest that ONO-1078 may prevent the antigen-induced production of TxB2 through the blockade of the activation of receptors by endogenously generated peptide leukotrienes.

Related Compounds

  • FPL 55712

Related Articles:

Strategies in the design of peptidoleukotriene antagonists.

1993-01-01

[J. Lipid Mediat. 6(1-3) , 265-73, (1993)]

Leukotriene receptor blockade in experimental heart failure.

1997-01-01

[Res. Exp. Med. (Berl.) 197(4) , 177-87, (1997)]

Leukotriene cysLT1 (LTD4) receptor antagonism of H1-antihistamines: an in vitro study.

1997-03-01

[Inflamm. Res. 46 Suppl 1 , S93-4, (1997)]

Effects of atropine, acetylsalicylic acid, FPL 55712, and phentolamine on increased histamine responsiveness of cat lung strips under conditions of airway inflammation.

1989-06-01

[Eur. Respir. J. 2(6) , 517-21, (1989)]

In vitro effect of DP-1904, a novel anti-asthma agent, against antigen-induced constriction and TXB2 release from the isolated guinea-pig lung parenchymal tissue.

1998-08-01

[Pharmacol. Res. 38(2) , 141-7, (1998)]

More Articles...